NaviFUS

NaviFUS operates at the intersection of therapeutic ultrasound, medical devices, CNS drug delivery, and clinical research. Its stated differentiation is the combination of neuronavigator-guided transcranial focused ultrasound with transient blood-brain barrier opening, allowing potential delivery of both small- and large-molecule therapies to targeted brain regions. The company also describes neuromodulation and sonodynamic therapy applications, broadening its platform beyond a single oncology use case. Within its disclosed category set, NaviFUS is more specialized than a general-purpose medical-device developer because its product strategy is tied to CNS therapeutics and pharmaceutical collaboration. Its secondary NAVIRFA Needle Tracking System adds an optical 3D guidance capability for needle-based interventions, but the central commercial thesis remains focused ultrasound-enabled drug delivery. The lack of publicly available valuation, pipeline economics, regulatory milestones, and detailed partner disclosures limits assessment of competitive scale.

NaviFUS’s trajectory shows a transition from a Taiwan-founded venture established in 2015 toward a financed therapeutic-ultrasound platform company. The company’s disclosed financing sequence includes $6 million in July 2016, $7 million in July 2018, $5.3 million in December 2020, and $10 million in August 2021, representing $28.3 million in amounts with disclosed values. The 2020 and 2021 rounds are the clearest recent capital inflection points and may have supported clinical development, device refinement, and expansion of pharmaceutical relationships. Its product scope has also broadened from blood-brain barrier opening and CNS drug delivery to neuromodulation, sonodynamic therapy, and optical needle tracking through the NAVIRFA system. Website materials reference clinical programs in Taiwan, Australia, and the United States. However, there is no employee-growth series, hiring activity, revenue information, regulatory timeline, or post-2021 financing disclosed here, making current momentum and commercialization progress difficult to quantify.